Tower Research Capital (TRC)’s Enzymotec Ltd ENZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-1,043
| Closed | -$12K | – | 4286 |
|
|
2017
Q4 | $12K | Sell |
1,043
-7,248
| -87% | -$84.1K | ﹤0.01% | 2475 |
|
|
2017
Q3 | $95K | Buy |
8,291
+1,566
| +23% | +$15.5K | 0.01% | 1416 |
|
|
2017
Q2 | $54K | Sell |
6,725
-695
| -9% | -$5.79K | 0.01% | 713 |
|
|
2017
Q1 | $65K | Buy |
7,420
+2,589
| +54% | +$21.9K | 0.01% | 632 |
|
|
2016
Q4 | $32K | Buy |
4,831
+4,310
| +827% | +$28.4K | ﹤0.01% | 1754 |
|
|
2016
Q3 | $4K | Buy |
+521
| New | +$4.17K | ﹤0.01% | 2775 |
|
|
2016
Q1 | – | Sell |
-147
| Closed | -$1K | – | 5466 |
|
|
2015
Q4 | $1K | Sell |
147
-60
| -29% | -$568 | ﹤0.01% | 4288 |
|
|
2015
Q3 | $2K | Buy |
+207
| New | +$1.85K | ﹤0.01% | 3493 |
|
|
2015
Q1 | – | Sell |
-160
| Closed | -$1K | – | 5259 |
|
|
2014
Q4 | $1K | Buy |
160
+60
| +60% | +$436 | ﹤0.01% | 3830 |
|
|
2014
Q3 | $1K | Sell |
100
-30
| -23% | -$324 | ﹤0.01% | 4238 |
|
|
2014
Q2 | $2K | Sell |
130
-198
| -60% | -$3.33K | ﹤0.01% | 3528 |
|
|
2014
Q1 | $7K | Buy |
328
+58
| +21% | +$1.54K | ﹤0.01% | 3022 |
|
|
2013
Q4 | $7K | Buy |
+270
| New | +$6.42K | ﹤0.01% | 3344 |
|
Tower Research Capital (TRC)'s ENZY Position: Q1 2018 in Review
Tower Research Capital (TRC) sold out of Enzymotec Ltd (ENZY) in Q1 2018, closing a stake of 1,043 shares — an estimated $12K sold.
Tower Research Capital (TRC) first reported a position in ENZY in Q4 2013 and held it in 13 quarters. The position peaked at $95K in Q3 2017. 0 funds tracked by Wall St. Rank hold ENZY as of Q1 2018.
- Tower Research Capital (TRC) reported no remaining Enzymotec Ltd position as of Q1 2018 after selling out during the quarter.
- Tower Research Capital (TRC) sold 1,043 Enzymotec Ltd shares in Q1 2018, an estimated $12K.
- Tower Research Capital (TRC) first reported a position in Enzymotec Ltd in Q4 2013 and held it in 13 quarters.
- Tower Research Capital (TRC)'s Enzymotec Ltd position peaked at $95K in Q3 2017.
- 0 funds tracked by Wall St. Rank held Enzymotec Ltd as of Q1 2018.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2018, filed 15 May 2018.